US › Healthcare

Ensysce Biosciences Inc (ENSC)

US · Healthcare · Biotechnology

$0.45+1.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.2M

Revenue YoY

-15.1%

Net profit

$-2.6M

EPS

$-0.20

EPS estimate

$-0.50

Net margin

-220.8%

EPS came in at -0.20 against a street estimate of -0.50 — a beat of 60.0%.

Key statistics

Market cap

$9.5M

Forward P/E

0.9

P/B

0.86

Book value

$-0.05

EPS (TTM)

$-2.56

52-week high

$2.75

52-week low

$0.23

50-day MA

$0.36

200-day MA

$0.57

Beta

0.98

Analyst view

Analysts rate Ensysce Biosciences Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $8.25.

Shareholding

Insiders

4.72%

Institutions

4.65%

Largest institutional holders

Fund	Stake
Adage Capital Partners Gp LLC	0.77%
Perceptive Advisors LLC	0.45%
Citadel Advisors Llc	0.44%
Geode Capital Management, LLC	0.38%
XTX Topco Ltd	0.13%
Vanguard Fiduciary Trust Co	0.12%
Jane Street Group LLC	0.07%
Virtu Financial LLC	0.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ensysce Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.